

Norberto Perico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3902616/publications.pdf>

Version: 2024-02-01

298
papers

126,502
citations

4653

85
h-index

326

287
g-index

310
all docs

310
docs citations

310
times ranked

139834
citing authors

#	ARTICLE	IF	CITATIONS
1	A comprehensive report of long-term stability data for a range ATMPs: A need to develop guidelines for safe and harmonized stability studies. <i>Cytotherapy</i> , 2022, 24, 544-556.	0.3	7
2	Glomerular hyperfiltration. <i>Nature Reviews Nephrology</i> , 2022, 18, 435-451.	4.1	60
3	Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990â€“2017. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 385-396.	0.8	34
4	Chronic kidney disease and neurological disorders: are uraemic toxins the missing piece of the puzzle?. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii33-ii44.	0.4	26
5	Albuminuria as a risk factor for mild cognitive impairment and dementiaâ€”what is the evidence?. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii55-ii62.	0.4	14
6	Third-party bone marrowâ€“derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial. <i>American Journal of Transplantation</i> , 2021, 21, 2795-2809.	2.6	20
7	Mapping child growth failure across low- and middle-income countries. <i>Nature</i> , 2020, 577, 231-234.	13.7	128
8	Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration. <i>Stem Cells Translational Medicine</i> , 2020, 9, 427-432.	1.6	20
9	Mapping disparities in education across low- and middle-income countries. <i>Nature</i> , 2020, 577, 235-238.	13.7	58
10	Global burden of 369 diseases and injuries in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1204-1222.	6.3	7,664
11	Global burden of 87 risk factors in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1223-1249.	6.3	3,928
12	Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950â€“2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1160-1203.	6.3	890
13	Five insights from the Global Burden of Disease Study 2019. <i>Lancet, The</i> , 2020, 396, 1135-1159.	6.3	335
14	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000â€“17. <i>The Lancet Global Health</i> , 2020, 8, e1038-e1060.	2.9	23
15	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000â€“17. <i>The Lancet Global Health</i> , 2020, 8, e1162-e1185.	2.9	91
16	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000â€“17: analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2020, 395, 1779-1801.	6.3	72
17	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2020, 395, 709-733.	6.3	2,858
18	The emergence of regenerative medicine in organ transplantation: 1st European Cell Therapy and Organ Regeneration Section meeting. <i>Transplant International</i> , 2020, 33, 833-840.	0.8	15

#	ARTICLE	IF	CITATIONS
19	Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017. <i>Nature Medicine</i> , 2020, 26, 750-759.	15.2	47
20	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 338-350.	2.1	17
21	Global, regional, and national burden of stroke, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology</i> , The, 2019, 18, 439-458.	4.9	2,005
22	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. <i>PLoS Medicine</i> , 2019, 16, e1002777.	3.9	42
23	The incessant search for renal biomarkers. <i>Current Opinion in Nephrology and Hypertension</i> , 2019, 28, 195-202.	1.0	4
24	Italy's health performance, 1990â€“2017: findings from the Global Burden of Disease Study 2017. <i>Lancet Public Health</i> , The, 2019, 4, e645-e657.	4.7	54
25	Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. <i>Transplantation</i> , 2019, 103, 1121-1130.	0.5	14
26	Proteinuria and Tubulotoxicity. , 2019, , 197-214.		2
27	Acute Renal Failure in Kidney Transplant Recipients. , 2019, , 1279-1285.e3.		0
28	Mesenchymal Stromal Cells for AKI after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 7-9.	3.0	7
29	Mesenchymal stromal cells for tolerance induction in organ transplantation. <i>Human Immunology</i> , 2018, 79, 304-313.	1.2	40
30	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. <i>Diabetes</i> , 2018, 67, 1414-1427.	0.3	136
31	Early and late scanning electron microscopy findings in diabetic kidney disease. <i>Scientific Reports</i> , 2018, 8, 4909.	1.6	29
32	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. <i>Lancet Diabetes and Endocrinology</i> , the, 2018, 6, 27-40.	5.5	24
33	Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 362-375.	3.0	55
34	Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the Global Burden of Disease 2015 study. <i>International Journal of Public Health</i> , 2018, 63, 177-186.	1.0	30
35	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1684-1735.	6.3	716
36	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1736-1788.	6.3	4,989

#	ARTICLE	IF	CITATIONS
37	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	6.3	3,269
38	Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	6.3	294
39	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	6.3	8,569
40	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 2091-2138.	6.3	335
41	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	6.3	2,123
42	A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases. <i>BMC Medical Research Methodology</i> , 2018, 18, 110.	1.4	2
43	Maternal and environmental risk factors for neonatal AKI and its long-term consequences. <i>Nature Reviews Nephrology</i> , 2018, 14, 688-703.	4.1	60
44	Disparities in Chronic Kidney Disease Prevalence among Males and Females in 195 Countries: Analysis of the Global Burden of Disease 2016 Study. <i>Nephron</i> , 2018, 139, 313-318.	0.9	156
45	Safety of Iohexol Administration to Measure Glomerular Filtration Rate in Different Patient Populations: A 25-Year Experience. <i>Nephron</i> , 2018, 140, 1-8.	0.9	21
46	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	6.3	638
47	Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 1359.	2.2	58
48	A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. <i>Lancet, The</i> , 2017, 390, 424-428.	6.3	125
49	Conversion from Brand-Name Neoral to the Generic Ciqorin in Stable Renal Transplant Recipients. <i>Nephron</i> , 2017, 135, 173-180.	0.9	4
50	Global Cardiovascular and Renal Outcomes of Reduced GFR. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2167-2179.	3.0	194
51	ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. <i>Current Opinion in Pharmacology</i> , 2017, 33, 34-40.	1.7	28
52	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2017, 390, 231-266.	6.3	480
53	Child and Adolescent Health From 1990 to 2015. <i>JAMA Pediatrics</i> , 2017, 171, 573.	3.3	306
54	Addressing acute kidney injury in critically ill newborn babies. <i>The Lancet Child and Adolescent Health</i> , 2017, 1, 161-163.	2.7	0

#	ARTICLE	IF	CITATIONS
55	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1084-1150.	6.3	573
56	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1260-1344.	6.3	1,589
57	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1151-1210.	6.3	3,565
58	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1211-1259.	6.3	5,578
59	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1345-1422.	6.3	1,879
60	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1423-1459.	6.3	284
61	Global, Regional, and National Levels of Maternal Mortality, 1990–2015: A Systematic Analysis for the Global Burden of Disease Study 2015. <i>Obstetrical and Gynecological Survey</i> , 2017, 72, 11-13.	0.2	41
62	The Impact of Kidney Development on the Life Course: A Consensus Document for Action. <i>Nephron</i> , 2017, 136, 3-49.	0.9	110
63	Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. <i>BMJ Global Health</i> , 2017, 2, e000453.	2.0	11
64	Should We Still Believe in Randomized Controlled Trials in Nephrology?. <i>Nephron</i> , 2017, 136, 281-286.	0.9	5
65	Epidemiology of End-Stage Renal Failure. , 2017, , 5-11.		7
66	Pharmacological Induction of Kidney Regeneration. , 2017, , 1025-1037.		4
67	Maintenance Immunosuppression in Kidney Transplantation. , 2017, , 259-276.		0
68	Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. <i>The Lancet Global Health</i> , 2016, 4, e307-e319.	2.9	350
69	Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1775-1812.	6.3	740
70	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	6.3	1,612
71	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	6.3	4,934
72	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	6.3	5,298

#	ARTICLE	IF	CITATIONS
73	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1659-1724.	6.3	4,203
74	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	6.3	571
75	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	6.3	413
76	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. <i>Lancet HIV,the</i> , 2016, 3, e361-e387.	2.1	461
77	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. <i>JAMA Pediatrics</i> , 2016, 170, 267.	3.3	479
78	Recent advances in immunosuppression and acquired immune tolerance in renal transplants. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, F446-F453.	1.3	5
79	Prevention programs for chronic kidney disease in low-income countries. <i>Internal and Emergency Medicine</i> , 2016, 11, 385-389.	1.0	28
80	Acute kidney injury in low-income and middle-income countries: no longer a death sentence. <i>The Lancet Global Health</i> , 2016, 4, e216-e217.	2.9	21
81	Mesenchymal stromal cells in renal transplantation: opportunities and challenges. <i>Nature Reviews Nephrology</i> , 2016, 12, 241-253.	4.1	132
82	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 785-794.	2.2	35
83	Sirtuin3 Dysfunction Is the Key Determinant of Skeletal Muscle Insulin Resistance by Angiotensin II. <i>PLoS ONE</i> , 2015, 10, e0127172.	1.1	16
84	Eliminating Treatable Deaths Due to Acute Kidney Injury in Resourceâ€“Poor Settings. <i>Seminars in Dialysis</i> , 2015, 28, 193-197.	0.7	18
85	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 743-800.	6.3	4,951
86	Effects of MCP-1 Inhibition by Bindarit Therapy in a Rat Model of Polycystic Kidney Disease. <i>Nephron</i> , 2015, 129, 52-61.	0.9	43
87	Maintenance Dialysis throughout the World in Years 1990 and 2010. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2621-2633.	3.0	159
88	Acute Kidney Injury in Poor Countries Should No Longer Be a Death Sentence: The ISN â€“O by 25' Project. <i>Annals of Nutrition and Metabolism</i> , 2015, 66, 42-44.	1.0	11
89	Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 79-85.	0.8	23
90	Acute kidney injury: more awareness needed, globally. <i>Lancet, The</i> , 2015, 386, 1425-1427.	6.3	20

#	ARTICLE	IF	CITATIONS
91	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	6.3	1,544
92	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2287-2323.	6.3	2,184
93	Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 385, 117-171.	6.3	5,847
94	Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1205-1214.	3.0	51
95	Need for chronic kidney disease prevention programs in disadvantaged populations. <i>Clinical Nephrology</i> , 2015, 83 (2015), 42-48.	0.4	7
96	Mesenchymal stromal cells to promote kidney transplantation tolerance. <i>Current Opinion in Organ Transplantation</i> , 2014, 19, 47-53.	0.8	30
97	Mortality landscape in the Global Burden of Diseases, Injuries and Risk Factors Study. <i>European Journal of Internal Medicine</i> , 2014, 25, 1-5.	1.0	19
98	Recellularization of Well-Preserved Acellular Kidney Scaffold Using Embryonic Stem Cells. <i>Tissue Engineering - Part A</i> , 2014, 20, 1486-1498.	1.6	169
99	Management of chronic kidney disease and its risk factors in eastern Nepal. <i>The Lancet Global Health</i> , 2014, 2, e506-e507.	2.9	15
100	High serum cholesterol: a missed risk factor for chronic kidney disease mortality. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 613-614.	5.5	3
101	Drug development: how academia, industry and authorities interact. <i>Nature Reviews Nephrology</i> , 2014, 10, 602-610.	4.1	4
102	Chronic kidney disease in sub-Saharan Africa: a public health priority. <i>The Lancet Global Health</i> , 2014, 2, e124-e125.	2.9	8
103	International Society of Nephrology’s Perspective on the Emergence of Chronic Kidney Diseases of Unknown/Undetermined Etiology. <i>MEDICC Review</i> , 2014, 16, 75.	0.5	8
104	Angiotensin II Contributes to Diabetic Renal Dysfunction in Rodents and Humans via Notch1/Snail Pathway. <i>American Journal of Pathology</i> , 2013, 183, 119-130.	1.9	39
105	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. <i>Transplant International</i> , 2013, 26, 867-878.	0.8	148
106	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2013, 382, 1485-1495.	6.3	218
107	Nature and Mediators of Parietal Epithelial Cell Activation in Glomerulonephritides of Human and Rat. <i>American Journal of Pathology</i> , 2013, 183, 1769-1778.	1.9	59
108	Kidney failure: aims for the next 10 years and barriers to success. <i>Lancet, The</i> , 2013, 382, 353-362.	6.3	50

#	ARTICLE	IF	CITATIONS
109	Multipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies. <i>Stem Cell Reviews and Reports</i> , 2013, 9, 65-79.	5.6	125
110	Mesenchymal stromal cells to promote solid organ transplantation tolerance. <i>Current Opinion in Organ Transplantation</i> , 2013, 18, 51-58.	0.8	70
111	Hypertension and kidney function in an adult population of West Bengal, India: Role of body weight, waist circumference, proteinuria and rural area living. <i>Nephrology</i> , 2013, 18, 798-807.	0.7	6
112	In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development. <i>Journal of Immunology</i> , 2013, 191, 2818-2828.	0.4	75
113	Community-Based Screening for Chronic Kidney Disease, Hypertension and Diabetes in Dharan. <i>Journal of the Nepal Medical Association</i> , 2013, 52, 205-212.	0.1	32
114	Prevalence of Hypertension and Diabetes and Coexistence of Chronic Kidney Disease and Cardiovascular Risk in the Population of the Republic of Moldova. <i>International Journal of Hypertension</i> , 2012, 2012, 1-8.	0.5	11
115	Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. <i>Kidney International</i> , 2012, 81, 903-918.	2.6	36
116	Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. <i>BMJ Open</i> , 2012, 2, bmjopen-2012-001357.	0.8	32
117	Chronic kidney disease: a research and public health priority. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iii19-iii26.	0.4	71
118	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. <i>Lancet</i> , The, 2012, 380, 2129-2143.	6.3	1,013
119	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet</i> , The, 2012, 380, 2197-2223.	6.3	7,061
120	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet</i> , The, 2012, 380, 2095-2128.	6.3	11,038
121	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet</i> , The, 2012, 380, 2163-2196.	6.3	6,376
122	Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study. <i>PLoS ONE</i> , 2012, 7, e32533.	1.1	46
123	Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 2373-2383.	2.6	151
124	Autologous Mesenchymal Stromal Cells and Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 412-422.	2.2	273
125	Intermediate Volume on Computed Tomography Imaging Defines a Fibrotic Compartment that Predicts Glomerular Filtration Rate Decline in Autosomal Dominant Polycystic Kidney Disease Patients. <i>American Journal of Pathology</i> , 2011, 179, 619-627.	1.9	19
126	Effects of high dose aleglitazar on renal function in patients with type 2 diabetes. <i>International Journal of Cardiology</i> , 2011, 151, 136-142.	0.8	29

#	ARTICLE	IF	CITATIONS
127	Aging and the kidney. <i>Current Opinion in Nephrology and Hypertension</i> , 2011, 20, 312-317.	1.0	40
128	Renal Graft Function and Low-Dose Cyclosporine Affect Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. <i>Transplantation</i> , 2011, 92, 550-556.	0.5	7
129	Omega-3 Polyunsaturated Fatty Acids Affect Sirolimus Exposure in Kidney Transplant Recipients on Calcineurin Inhibitor-Free Regimen. <i>Transplantation</i> , 2010, 89, 126-127.	0.5	3
130	Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT). <i>Transplantation</i> , 2010, 90, 124-126.	0.5	66
131	Burden of CKD, Proteinuria, and Cardiovascular Risk Among Chinese, Mongolian, and Nepalese Participants in the International Society of Nephrology Screening Programs. <i>American Journal of Kidney Diseases</i> , 2010, 56, 915-927.	2.1	58
132	Predicting Cisplatin-Induced Acute Kidney Injury by Urinary Neutrophil Gelatinase-Associated Lipocalin Excretion: A Pilot Prospective Case-Control Study. <i>Nephron Clinical Practice</i> , 2010, 115, c154-c160.	2.3	79
133	Do mTOR inhibitors still have a future in ADPKD?. <i>Nature Reviews Nephrology</i> , 2010, 6, 696-698.	4.1	13
134	Sirolimus Therapy to Halt the Progression of ADPKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1031-1040.	3.0	157
135	Non-immune interventions to protect kidney allografts in the long term. <i>Kidney International</i> , 2010, 78, S71-S75.	2.6	17
136	Limited Sampling Strategies for the Estimation of Sirolimus Daily Exposure in Kidney Transplant Recipients on a Calcineurin Inhibitor-Free Regimen. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 773-781.	1.0	7
137	Hepatitis C Infection and Chronic Renal Diseases. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 207-220.	2.2	184
138	Aldosterone and progression of kidney disease. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2009, 3, 133-143.	1.0	18
139	Screening for chronic kidney disease in emerging countries: feasibility and hurdles. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1355-1358.	0.4	37
140	V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. <i>Kidney International</i> , 2009, 76, 960-967.	2.6	56
141	ABCB1 Genotypes Predict Cyclosporine-Related Adverse Events and Kidney Allograft Outcome. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1404-1415.	3.0	60
142	Kidney Injury Molecule 1: In Search of Biomarkers of Chronic Tubulointerstitial Damage and Disease Progression. <i>American Journal of Kidney Diseases</i> , 2009, 53, 1-4.	2.1	123
143	Bone Marrow-Derived Mesenchymal Stem Cells Improve Islet Graft Function in Diabetic Rats. <i>Transplantation Proceedings</i> , 2009, 41, 1797-1800.	0.3	126
144	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. <i>Transplantation</i> , 2009, 88, 614-619.	0.5	64

#	ARTICLE	IF	CITATIONS
145	Acute Renal Failure in Kidney Transplant Recipients. , 2009, , 1660-1665.		0
146	Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice. Stem Cells, 2008, 26, 2075-2082.	1.4	351
147	Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nature Reviews Drug Discovery, 2008, 7, 936-953.	21.5	77
148	Pharmacogenetics of Immunosuppressants: Progress, Pitfalls and Promises. American Journal of Transplantation, 2008, 8, 1374-1383.	2.6	39
149	Investigational drugs for diabetic nephropathy. Expert Opinion on Investigational Drugs, 2008, 17, 1487-1500.	1.9	11
150	Determination of Atazanavir in Human Plasma by High-Performance Liquid Chromatography With UV Detection. Journal of Chromatographic Science, 2008, 46, 485-489.	0.7	15
151	Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells. Journal of Immunology, 2008, 181, 3933-3946.	0.4	405
152	The Aggravating Mechanisms of Aldosterone on Kidney Fibrosis. Journal of the American Society of Nephrology: JASN, 2008, 19, 1459-1462.	3.0	99
153	Pharmacokinetic/Pharmacodynamic Drug Interaction Between Rosiglitazone and Mycophenolate Mofetil in Kidney Transplantation: A Case Report. Transplantation, 2008, 85, 921-922.	0.5	10
154	Inhibition of TGF- β 2 expression: A novel role for thiazolidinediones to implement renoprotection in diabetes. Kidney International, 2007, 72, 1419-1421.	2.6	10
155	Effects of Rosuvastatin on Glomerular Capillary Size-Selectivity Function in Rats with Renal Mass Ablation. American Journal of Nephrology, 2007, 27, 630-638.	1.4	12
156	Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. Kidney International, 2007, 71, 1132-1141.	2.6	3
157	C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics, 2007, 8, 1127-1141.	0.6	86
158	Regulatory T Cells and T Cell Depletion: Role of Immunosuppressive Drugs. Journal of the American Society of Nephrology: JASN, 2007, 18, 1007-1018.	3.0	224
159	More on Renal Disease Progression: Is Interstitial Inflammation Truly Protective?. Journal of the American Society of Nephrology: JASN, 2007, 18, 1630-1632.	3.0	1
160	Pharmacokinetics of Mycophenolate Sodium and Comparison with the Mofetil Formulation in Stable Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1147-1155.	2.2	53
161	Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury. Transplantation, 2007, 84, 956-964.	0.5	94
162	Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection. Clinica Chimica Acta, 2006, 364, 354-358.	0.5	35

#	ARTICLE	IF	CITATIONS
163	Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?. <i>Journal of Hepatology</i> , 2006, 44, 837-838.	1.8	5
164	Corrigendum to "Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?" [Hepato 44 (2006) 837-838]. <i>Journal of Hepatology</i> , 2006, 45, 339.	1.8	0
165	Mycophenolic Acid Formulation Affects Cyclosporine Pharmacokinetics in Stable Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 643-649.	1.0	3
166	Prevention programmes of progressive renal disease in developing nations (Review Article). <i>Nephrology</i> , 2006, 11, 321-328.	0.7	53
167	Comparison of the Innofluor® certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. <i>Clinical Biochemistry</i> , 2006, 39, 1152-1159.	0.8	19
168	Long-Term Renal Allograft Function on a Tacrolimus-Based, Pred-Free Maintenance Immunosuppression Comparing Sirolimus vs. MMF+.. <i>American Journal of Transplantation</i> , 2006, 6, 1617-1623.	2.6	68
169	Ways to Boost Kidney Transplant Viability: A Real Need for the Best Use of Older Donors. <i>American Journal of Transplantation</i> , 2006, 6, 2543-2547.	2.6	37
170	Timed Urine Collections Are Not Needed to Measure Urine Protein Excretion in Clinical Practice. <i>American Journal of Kidney Diseases</i> , 2006, 47, 1-7.	2.1	81
171	Cyclosporine Formulation and Kaposi's Sarcoma after Renal Transplantation. <i>Transplantation</i> , 2005, 80, 743-748.	0.5	14
172	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 95-105.	0.2	4
173	High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 816, 99-105.	1.2	30
174	The scientific care for prevention: An overview. <i>Kidney International</i> , 2005, 67, S8-S13.	2.6	3
175	Pathophysiology of disease progression in proteinuric nephropathies. <i>Kidney International</i> , 2005, 67, S79-S82.	2.6	24
176	Kidney prevention recipes for your office practice. <i>Kidney International</i> , 2005, 67, S136-S141.	2.6	5
177	Strategies for national health care systems in emerging countries: The case of screening and prevention of renal disease progression in Bolivia. <i>Kidney International</i> , 2005, 68, S87-S94.	2.6	46
178	The future of renoprotection. <i>Kidney International</i> , 2005, 68, S95-S101.	2.6	18
179	Prevention of progression and remission/regression strategies for chronic renal diseases: Can we do better now than five years ago?. <i>Kidney International</i> , 2005, 68, S21-S24.	2.6	17
180	The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. <i>Kidney International</i> , 2005, 68, S57-S65.	2.6	381

#	ARTICLE	IF	CITATIONS
181	Generic cyclosporine formulations: more open questions than answers. <i>Transplant International</i> , 2005, 18, 371-378.	0.8	29
182	Hemolytic Uremic Syndrome: A Fatal Outcome after Kidney and Liver Transplantation Performed to Correct Factor H Gene Mutation. <i>American Journal of Transplantation</i> , 2005, 5, 1146-1150.	2.6	116
183	Assessing Renal Function by GFR Prediction Equations in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 1175-1176.	2.6	19
184	Influence of Co-Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 2937-2944.	2.6	72
185	Dual Blockade of the Renin-Angiotensin System: The Ultimate Treatment for Renal Protection?. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, S34-S38.	3.0	24
186	Emerging drugs for diabetic nephropathy. <i>Expert Opinion on Emerging Drugs</i> , 2005, 10, 747-771.	1.0	9
187	Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: Not simply overestimation. <i>Clinica Chimica Acta</i> , 2005, 355, 153-164.	0.5	15
188	Blood Cyclosporine Level Soon After Kidney Transplantation is a Major Determinant of Rejection: Insights From the Mycophenolate Steroid-Sparing Trial. <i>Transplantation Proceedings</i> , 2005, 37, 2037-2040.	0.3	8
189	Mechanisms of Disease: pre-eclampsia. <i>Nature Clinical Practice Nephrology</i> , 2005, 1, 98-114.	2.0	259
190	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 95-105.	0.2	1
191	The Bergamo Kidney Transplant Program. <i>Clinical Transplants</i> , 2005, , 85-100.	0.2	0
192	Hyperuricemia in Kidney Transplantation. , 2004, 147, 124-131.		25
193	Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. <i>Expert Opinion on Therapeutic Patents</i> , 2004, 14, 1553-1566.	2.4	5
194	Targeted Deletion of Angiotensin II Type 1A Receptor Does not Protect Mice from Progressive Nephropathy of Overload Proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2666-2674.	3.0	31
195	In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial. <i>Kidney International</i> , 2004, 65, 1084-1090.	2.6	24
196	From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy. <i>American Journal of Transplantation</i> , 2004, 4, 299-310.	2.6	58
197	Therapeutic Drug Monitoring of Sirolimus: Effect of Concomitant Immunosuppressive Therapy and Optimization of Drug Dosing. <i>American Journal of Transplantation</i> , 2004, 4, 1345-1351.	2.6	57
198	Performance of Different Prediction Equations for Estimating Renal Function in Kidney Transplantation. <i>American Journal of Transplantation</i> , 2004, 4, 1826-1835.	2.6	184

#	ARTICLE	IF	CITATIONS
199	The potential of endothelin antagonism as a therapeutic approach. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1419-1435.	1.9	12
200	Mesenchymal Stem Cells Are Renotropic, Helping to Repair the Kidney and Improve Function in Acute Renal Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1794-1804.	3.0	690
201	Losartan in diabetic nephropathy. <i>Expert Review of Cardiovascular Therapy</i> , 2004, 2, 473-483.	0.6	14
202	Nephrotoxic aspects of cyclosporine. <i>Transplantation Proceedings</i> , 2004, 36, S234-S239.	0.3	67
203	Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. <i>Lancet, The</i> , 2004, 364, 503-512.	6.3	155
204	Delayed graft function in kidney transplantation. <i>Lancet, The</i> , 2004, 364, 1814-1827.	6.3	828
205	Donor hematopoietic cells: central versus peripheral tolerance. <i>Current Opinion in Organ Transplantation</i> , 2004, 9, 284-288.	0.8	0
206	Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. <i>Personalized Medicine</i> , 2004, 1, 53-62.	0.8	1
207	ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. <i>Kidney International</i> , 2003, 64, 2253-2261.	2.6	30
208	Preventing end-stage renal disease: The potential impact of screening and intervention in developing countries. <i>Kidney International</i> , 2003, 63, 1948-1950.	2.6	21
209	Renal Transplantation: Can We Reduce Calcineurin Inhibitor/Stop Steroids? Evidence Based on Protocol Biopsy Findings. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 755-766.	3.0	27
210	Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 858-859.	0.4	24
211	Calcineurin inhibitors and sirolimus. , 2003, , 403-458.		1
212	Tackling the Shortage of Donor Kidneys: How to Use the Best that We Have. <i>American Journal of Nephrology</i> , 2003, 23, 245-259.	1.4	81
213	Routine renin-angiotensin system blockade in renal transplantation?. <i>Current Opinion in Nephrology and Hypertension</i> , 2002, 11, 1-10.	1.0	22
214	Chronic Renal Diseases: Renoprotective Benefits of Renin-angiotensin System Inhibition. <i>Annals of Internal Medicine</i> , 2002, 136, 604.	2.0	235
215	Nitric oxide and renal perfusion in humans. <i>Journal of Hypertension</i> , 2002, 20, 391-393.	0.3	2
216	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. <i>Blood</i> , 2002, 100, 778-785.	0.6	200

#	ARTICLE	IF	CITATIONS
217	Tacrolimus and ciclosporin microemulsion in renal transplantation. <i>Lancet</i> , The, 2002, 360, 799.	6.3	0
218	One or two marginal organs for kidney transplantation?. <i>Transplantation Proceedings</i> , 2002, 34, 3091-3096.	0.3	9
219	Xenotransplantation in the 21st Century. <i>Blood Purification</i> , 2002, 20, 45-54.	0.9	10
220	Conflict of interest as seen from a researcher's perspective. <i>Science and Engineering Ethics</i> , 2002, 8, 337-342.	1.7	4
221	Assessment of sirolimus concentrations in whole blood by high-performance liquid chromatography with ultraviolet detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 774, 187-194.	1.2	25
222	Propionyl-L-carnitine prevents renal function deterioration due to ischemia/reperfusion. <i>Kidney International</i> , 2002, 61, 1064-1078.	2.6	61
223	Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. <i>Kidney International</i> , 2002, 62, 1060-1067.	2.6	214
224	New therapeutics that antagonize endothelin: promises and frustrations. <i>Nature Reviews Drug Discovery</i> , 2002, 1, 986-1001.	21.5	130
225	Optimization of cyclosporine therapy in the neoral era: abbreviated AUC, single blood sampling?. <i>Transplantation Proceedings</i> , 2001, 33, 3117-3119.	0.3	11
226	Whole-Blood Calcineurin Activity Is Not Predicted by Cyclosporine Blood Concentration in Renal Transplant Recipients. <i>Clinical Chemistry</i> , 2001, 47, 1679-1687.	1.5	56
227	Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. <i>Current Opinion in Nephrology and Hypertension</i> , 2001, 10, 1-6.	1.0	23
228	Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. <i>Clinical Transplantation</i> , 2001, 15, 402-409.	0.8	75
229	IMMUNOMODULATION BY INTRATHYMIC INJECTION OF DONOR LEUKOCYTES IN RHESUS MONKEYS1. <i>Transplantation</i> , 2001, 72, 1432-1436.	0.5	7
230	Thymic Microchimerism Correlates with the Outcome of Tolerance-Inducing Protocols for Solid Organ Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2815-2826.	3.0	25
231	Combined Treatment with Mycophenolate Mofetil and an Angiotensin II Receptor Antagonist Fully Protects from Chronic Rejection in a Rat Model of Renal Allograft. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1937-1946.	3.0	32
232	Molecular Medicine in Organ Transplantation: How and When?. , 2001, , 317-334.		0
233	Pharmacologic Monitoring of Immunosuppressive Drugs. , 2001, , 43-59.		0
234	Immunomodulation by intrathymic injection of donor leukocytes in rhesus monkeys. <i>Transplantation</i> 2001; 72: 1432.. <i>Transplantation</i> , 2001, 72, 1351-1352.	0.5	0

#	ARTICLE	IF	CITATIONS
235	Endothelin Antagonists and Renal Protection. Journal of Cardiovascular Pharmacology, 2000, 35, S75-S78.	0.8	27
236	Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney International, 1999, 55, 674-685.	2.6	93
237	Peripheral donor leukocytes prolong survival of rat renal allografts. Kidney International, 1999, 56, 1101-1112.	2.6	33
238	ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. American Journal of Kidney Diseases, 1999, 34, 626-632.	2.1	62
239	Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. American Journal of Kidney Diseases, 1999, 33, 267-275.	2.1	34
240	Peripheral donor leukocytes prolong survival of rat renal allografts. Kidney International, 1999, 56, 1101.	2.6	14
241	Antiproteinuric Therapy while Preventing the Abnormal Protein Traffic in Proximal Tubule Abrogates Protein- and Complement-Dependent Interstitial Inflammation in Experimental Renal Disease. Journal of the American Society of Nephrology: JASN, 1999, 10, 804-813.	3.0	99
242	Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Kidney International, 1998, 54, 2146-2150.	2.6	26
243	Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients. Transplantation Proceedings, 1998, 30, 1654-1655.	0.3	1
244	Optimization of cyclosporine therapy in kidney transplantation. Transplantation Proceedings, 1998, 30, 1673-1676.	0.3	1
245	Application of newer clearance techniques for the determination of glomerular filtration rate. Current Opinion in Nephrology and Hypertension, 1998, 7, 675-680.	1.0	74
246	Angiotensin II receptor antagonists and treatment of hypertension and renal disease. Current Opinion in Nephrology and Hypertension, 1998, 7, 571-578.	1.0	16
247	Cyclosporine/tacrolimus (FK-506). , 1998, , 275-300.		2
248	Pharmacological and clinical profile of valsartan. Drugs of Today, 1998, 34, 973.	0.7	8
249	The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.. Journal of the American Society of Nephrology: JASN, 1998, 9, 2308-2317.	3.0	64
250	Prevention of Transplant Rejection. Drugs, 1997, 54, 533-570.	4.9	80
251	Efficacy and Tolerability of Valsartan Compared with Lisinopril in Patients with Hypertension and Renal Insufficiency. Clinical Drug Investigation, 1997, 14, 252-259.	1.1	15
252	Acquired transplant tolerance. International Journal of Clinical and Laboratory Research, 1997, 27, 165-177.	1.0	15

#	ARTICLE	IF	CITATIONS
253	SEQUENTIAL MONITORING OF URINE-SOLUBLE INTERLEUKIN 2 RECEPTOR AND INTERLEUKIN 6 PREDICTS ACUTE REJECTION OF HUMAN RENAL ALLOGRAFTS BEFORE CLINICAL OR LABORATORY SIGNS OF RENAL DYSFUNCTION. <i>Transplantation</i> , 1997, 63, 1508-1514.	0.5	53
254	Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: New antirejection drugs. <i>Expert Opinion on Therapeutic Patents</i> , 1996, 6, 871-891.	2.4	4
255	Cyclosporine induces glomerulosclerosis: Three-dimensional definition of the lesions in a rat model of renal transplant. <i>Kidney International</i> , 1996, 49, 1283-1288.	2.6	34
256	CTLA4lg ALONE OR IN COMBINATION WITH LOW-DOSE CYCLOSPORINE FAILS TO REVERSE ACUTE REJECTION OF RENAL ALLOGRAFT IN THE RAT. <i>Transplantation</i> , 1996, 61, 1320-1322.	0.5	12
257	RECOVERY OF BLOOD MONONUCLEAR CELL CALCINEURIN ACTIVITY SEGREGATES TWO POPULATIONS OF RENAL TRANSPLANT PATIENTS WITH DIFFERENT SENSITIVITIES TO CYCLOSPORINE INHIBITION. <i>Transplantation</i> , 1996, 61, 1526-1531.	0.5	22
258	Toward novel antirejection strategies: In vivo immunosuppressive properties of CTLA4lg. <i>Kidney International</i> , 1995, 47, 241-246.	2.6	30
259	Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides.. <i>Journal of Experimental Medicine</i> , 1994, 180, 1967-1972.	4.2	36
260	Following an Initial Decline, Glomerular Filtration Rate Stabilizes in Heart Transplant Patients on Chronic Cyclosporine. <i>American Journal of Kidney Diseases</i> , 1994, 24, 549-553.	2.1	32
261	MECHANISMS OF ACQUIRED THYMIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. <i>Transplantation</i> , 1994, 58, 125-132.	0.5	124
262	Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. <i>Kidney International</i> , 1993, 43, 706-711.	2.6	189
263	Failure to predict cyclosporine area under the curve using a limited sampling strategy. <i>Kidney International</i> , 1993, 44, 436-439.	2.6	21
264	Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. <i>Kidney International</i> , 1993, 43, 354-358.	2.6	153
265	Edema of the Nephrotic Syndrome: The Role of the Atrial Peptide System. <i>American Journal of Kidney Diseases</i> , 1993, 22, 355-366.	2.1	38
266	Renal Handling of Sodium in the Nephrotic Syndrome. <i>American Journal of Nephrology</i> , 1993, 13, 413-421.	1.4	13
267	THYMIC RECOGNITION OF CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX ALLOPEPTIDES INDUCES DONOR-SPECIFIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. <i>Transplantation</i> , 1993, 56, 461-465.	0.5	133
268	Colchicine allows prolonged survival of highly reactive renal allograft in the rat.. <i>Journal of the American Society of Nephrology: JASN</i> , 1993, 4, 1294-1299.	3.0	11
269	Atrial Natriuretic Peptide and Prostacyclin Synergistically Mediate Hyperfiltration and Hyperperfusion of Diabetic Rats. <i>Diabetes</i> , 1992, 41, 533-538.	0.3	49
270	THE ACUTE EFFECT OF FK506 AND CYCLOSPORINE ON ENDOTHELIAL CELL FUNCTION AND RENAL VASCULAR RESISTANCE. <i>Transplantation</i> , 1992, 54, 775-779.	0.5	84

#	ARTICLE	IF	CITATIONS
271	DAILY RENAL HYPOPERFUSION INDUCED BY CYCLOSPORINE IN PATIENTS WITH RENAL TRANSPLANTATION. Transplantation, 1992, 54, 56-60.	0.5	151
272	Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet, The, 1992, 339, 1421.	6.3	30
273	Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. American Journal of Medicine, 1992, 92, S60-S63.	0.6	31
274	Turnour necrosis factor stimulates endothelin-1 gene expression in cultured bovine endothelial cells. Mediators of Inflammation, 1992, 1, 263-266.	1.4	4
275	Measurement of GFR with a single intravenous injection of nonradioactive iothalamate. Kidney International, 1992, 41, 1081-1084.	2.6	33
276	Analysis by fast atom bombardment mass spectrometry of phospholipids from tubuli, glomeruli, and urine of normal rats and rats with acute renal failure. Biochemical Medicine and Metabolic Biology, 1992, 48, 219-226.	0.7	1
277	Induction of unresponsiveness via intrathymic inoculation. Lancet, The, 1991, 338, 450.	6.3	4
278	Morphometrical Analysis of Glomerular Changes Induced by Cyclosporine in the Rat. American Journal of Kidney Diseases, 1991, 17, 537-543.	2.1	8
279	Cyclosporine-induced renal dysfunction in experimental animals and humans. Transplantation Reviews, 1991, 5, 63-80.	1.2	23
280	Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation. Lancet, The, 1991, 337, 750-752.	6.3	131
281	CO-PARTICIPATION OF THROMBOXANE A2 AND LEUKOTRIENE C4 AND D4 IN MEDIATING CYCLOSPORINE-INDUCED ACUTE RENAL FAILURE. Transplantation, 1991, 52, 873-878.	0.5	22
282	Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney International, 1991, 40, 243-250.	2.6	105
283	Mechanisms and Mediators of Cyclosporine-Induced Renal Vascular Changes. , 1991, , 543-554.		0
284	Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. Kidney International, 1990, 38, 447-458.	2.6	28
285	Endothelin and eicosanoid synthesis in cultured mesangial cells. Kidney International, 1990, 37, 927-933.	2.6	26
286	Ticlopidine prevents renal disease progression in rats with reduced renal mass. Kidney International, 1990, 37, 934-942.	2.6	33
287	Role of Platelet-Activating Factor in Renal Immune Injury and Proteinuria. American Journal of Nephrology, 1990, 10, 98-104.	1.4	16
288	Functional implications of decreased renal cortical atrial natriuretic peptide binding in experimental diabetes.. Circulation Research, 1990, 66, 1453-1460.	2.0	15

#	ARTICLE	IF	CITATIONS
289	Role of Insulin and Atrial Natriuretic Peptide in Sodium Retention in Insulin-Treated IDDM Patients During Isotonic Volume Expansion. <i>Diabetes</i> , 1990, 39, 289-298.	0.3	118
290	Role of endothelium-derived nitric oxide in the bleeding tendency of uremia.. <i>Journal of Clinical Investigation</i> , 1990, 86, 1768-1771.	3.9	110
291	Abnormalities of Arachidonate Metabolism in Experimental Ciclosporin Nephrotoxicity. <i>American Journal of Nephrology</i> , 1989, 9, 72-77.	1.4	8
292	Effects of Tertatolol on Renal Function in the Isolated Perfused Rat Kidney. <i>American Journal of Hypertension</i> , 1989, 2, 223S-227S.	1.0	4
293	Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. <i>Kidney International</i> , 1989, 36, 57-64.	2.6	57
294	Abnormalities in arachidonic acid metabolites in nephrotoxic glomerular injury. <i>Toxicology Letters</i> , 1989, 46, 65-75.	0.4	8
295	Metabolism of thromboxane B2 in the isolated perfused rat kidney: mass spectrometric identification of urinary products. <i>Lipids and Lipid Metabolism</i> , 1989, 1006, 167-172.	2.6	6
296	Increased urinary excretion of thromboxane B2 and 2,3-dinor-TxB2 in cyclosporin A nephrotoxicity. <i>Kidney International</i> , 1988, 34, 164-174.	2.6	69
297	Pathogenesis of Preeclampsia. , 1986, , 13-33.		5
298	The Lupus Anticoagulant. <i>Experimental Biology and Medicine</i> , 1984, 176, 337-341.	1.1	10